NEFL and proximal spinal muscular atrophy: NfL may also play a potential role as pharmacodynamic biomarker in response to therapeutic interventions, as demonstrated in SMA following treatment with nusinersen (Spinraza).29 This may be particularly relevant in pediatric populations where functional measures are less sensitive or disease evolution occurs more slowly.30